QuidelOrtho Corp. operates as a vitro diagnostics company. The company is headquartered in San Diego, California and currently employs 6,500 full-time employees. The firm specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. The company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.
How did QDEL's recent EPS compare to expectations?
The most recent EPS for QuidelOrtho Corp is $0.46, beating expectations of $0.43.
How did QuidelOrtho Corp QDEL's revenue perform in the last quarter?
QuidelOrtho Corp revenue for the last quarter is $0.46
What is the revenue estimate for QuidelOrtho Corp?
According to 10 of Wall street analyst, the revenue estimate of QuidelOrtho Corp range from $669.02M to $575.26M
What's the earning quality score for QuidelOrtho Corp?
QuidelOrtho Corp has a earning quality score of B+/57.186306. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does QuidelOrtho Corp report earnings?
QuidelOrtho Corp next earnings report is expected in 2026-05-12
What are QuidelOrtho Corp's expected earnings?
QuidelOrtho Corp expected earnings is $722.59M, according to wall-street analysts.
Did QuidelOrtho Corp beat earnings expectations?
QuidelOrtho Corp recent earnings of $723.6M beat expectations.